A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients progressing aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Nancy U., Winer, Eric P., Wheatley, Duncan, Carey, Lisa A., Houston, Stephen, Mendelson, David, Munster, Pamela, Frakes, Laurie, Kelly, Steve, Garcia, Agustin A., Cleator, Susan, Uttenreuther-Fischer, Martina, Jones, Hilary, Wind, Sven, Vinisko, Richard, Hickish, Tamas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387495/
https://www.ncbi.nlm.nih.gov/pubmed/22418700
http://dx.doi.org/10.1007/s10549-012-2003-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387495/
https://www.ncbi.nlm.nih.gov/pubmed/22418700
http://dx.doi.org/10.1007/s10549-012-2003-y

Ejemplares similares